Keywords
Tamizare
Preeclampsia
Embarazo de alto riesgo
Prevención Hypertension pregnancy induced
Mass screening
Pre-Eclampsia
Pregnancy high risk
prevention
How to Cite
Abstract
Introduction: Screening for hypertensive disorders of pregnancy performed in the first trimester can identify patients at high risk for these outcomes, for closer monitoring and administration of prophylactic Aspirin according to the evidence. Objective: In this review we show the current state of this screening and what has been done in other countries and in Colombia. Materials and Methods: A search of the literature was made in PubMed database using the Mesh terms, Hypertension, Pregnancy-Induced, Mass Screening, Pre-Eclampsia. Results: The screening models that combine several factors are effective in predicting preeclampsia, especially early onset. Conclusions: studies are required to validate these tests and to evaluate its cost-effectiveness.
References
Herrera J, Herrera R, Herrera JP. Reducción de la mortalidad materna por Preeclampsia en Colombia - un análisis de series de tiempo interrumpido. Colombia Médica. 2014;45(1).
Duley L, Henderson D, Meher S, King J. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane. 2007. https://doi.org/10.1002/14651858.CD004659.pub2
Bujold E, Roberge S, Nicolaides K. Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation. Prnatal Diagnosis. 2014;34(1-7). https://doi.org/10.1002/pd.4403
ACOG. Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstetrics and Gynecology. 2013;122(5):1122-31.
Cinets. RdGDdlG-UNdCA. Guia de Práctica Clínica para el abordaje de las complicaciones hipertensivas asociadas al embarazo. Revista Colombiana de Obstetricia y Ginecología. 2013;64(3):289-326. https://doi.org/10.18597/rcog.107
Organization. WH. Prevention and treatment of pre-eclampsia and eclampsia. 2011.
ACOG. Diagnosis and management of preeclampsia and eclampsia. Practice Bulletin No. 33. Obstetrics and Gynecology. 2002;99:159-67. https://doi.org/10.1097/00006250-200201000-00028
Díaz Martinez L, Serrano Díaz N. Oportunidades de investigación en preeclampsia, desde la perspectiva de prevención primaria. Un artículo de reflexión. Revista Colombiana de Obstetricia y Ginecología. 2008;59(3):206 - 15. https://doi.org/10.18597/rcog.405
Colombia MdSyPSRd. Guía de promoción de la salud y prevención de enfermedades en la salud pública. Guía 14. Guía de las complicaciones hipertensivas asociadas con el embarazo. 2007.
Poon L, Kametas N, Chelemen T, Leal A, Nicolaides K. Maternal risk factors for hypertensive disorders in pregnancy:
a multivariate approach. J Hum Hypertens. 2010;24:104-10. https://doi.org/10.1038/jhh.2009.45
Redman C, Sargent I. Latest advances in understanding preeclampsia. Science. 2005;308. https://doi.org/10.1126/science.1111726
Cnossen J, Morris R. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine
growth restriction: a systematic review and bivariable metaanalysis. Can Med Assoc J. 2008;178:701-11. https://doi.org/10.1503/cmaj.070430
Plasencia W, Maiz N, Poon L, Nicolaides K. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of preeclampsia. Ultrasound Obstet Gynecol. 2008;32:138 - 46. https://doi.org/10.1002/uog.5402
Anderson U, Olsson M, Kristensen K, Åkerström B. Review: Biochemical markers to predict preeclampsia. Placenta. 2012;26. https://doi.org/10.1016/j.placenta.2011.11.021
Tanuja L, Chikkala R, Ratnakar K. Biomarkers for the management of pre-eclampsia in pregnant women. The Indian Journal of Medical Research. 2013;138(1).
Akolekar R, Syngelaki A, Sarquis R, Mona Z, Nicolaides K. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11 - 13 weeks. Prenatal Diagnosis. 2011(31):66-74. https://doi.org/10.1002/pd.2660
Audibert F. Maternal serum screening for preeclampsia: is performance enough? Clin Biochem. 2010;43:707-8. https://doi.org/10.1016/j.clinbiochem.2010.03.004
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides K. Competing Risks Model in EarlyScreening for Preeclampsia byBiophysical and Biochemical Markers. Fetal diagnosis and Therapy. 2013;33:8-15. https://doi.org/10.1159/000341264
Park F, Leung C, Poon L, Williams P, Rothwell S. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology 2013;53:532-9. https://doi.org/10.1111/ajo.12126
Oliveira N, Magder L, Blitzer M, Baschat A. First Trimester Prediction of Preeclampsia: External validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol. 2014;10. https://doi.org/10.1002/uog.13435
Excellence LNIfHaC. Hypertension in pregnancy. Clinical guideline 107. 2011.
Serrano N. Immunology and genetic of preeclampsia. Clinical & Developmental Immunology. 2006;13:197 - 201. https://doi.org/10.1080/17402520600876903
Morgan F, Calderón S, Martínez J. Factores de riesgo asociados con preeclampsia: estudio de casos y controles. Ginecologia y Obstetricia y de México. 2010;78(3):153-9.